Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Meprednisone

FDA-approved product (tablet, oral), marketed as Betapar.

Registered studies
2
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Meprednisone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Meprednisone. Its therapeutic class is shown instead.

WHO therapeutic group
Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Meprednisone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Meprednisone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Methylprednisolone Combined Electric-acupuncture on Cognitive Function

    NCT02535039 · start 2015-10

    Registered record
    Registry ID
    NCT02535039
    Conditions
    Postoperative Complication; Cognitive Retention Disorder
    Interventions
    Methylprednisolone; Physiological saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2016-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Complication; Cognitive Retention Disorder
    InterventionMethylprednisolone; Physiological saline
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

    NCT00623766 · start 2008-07

    Registered record
    Registry ID
    NCT00623766
    Conditions
    Melanoma
    Interventions
    Ipilimumab; Corticosteroid: Betamethasone; Corticosteroid: Dexamethasone; Corticosteroid: Fludrocortisone; Corticosteroid: Hydrocortisone; Corticosteroid: Meprednisone; Corticosteroid: Methylprednisolone; Corticosteroid: Prednisolone; Corticosteroid: Prednisone; Corticosteroid: Triamcinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07
    Completion
    2012-10
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionIpilimumab; Corticosteroid: Betamethasone; Corticosteroid: Dexamethasone; Corticosteroid: Fludrocortisone +6 more
    PhasePhase 2
    Registry statusCompleted